RAD June 2024 Abstracts and Posters
707 Contemporary systemic treatment patterns in atopic dermatitis
Ann P. Quick, Lenka V. Hurton, Olga Zolochevska, Aaron S. Farberg, Matthew S. Goldberg, Jonathan I. Silverberg
708 Raising the bar of efficacy in atopic dermatitis: lebrikizumab maintains depth of response over 2 years
Eric Simpson, Tilo Biedermann, Leon Kircik, Raj Chovatiya, Ignasi Figueras-Nart, Marta Casillas, Gaia Gallo, Yuxin Ding, Chaoran Hu, Evangeline Pierce, Helena Agell, Christian Vestergaard
709 Greater levels of itch relief and skin clearance correlate with improved patient outcomes in atopic dermatitis – Real-world insights from TARGET-DERM AD
Jonathan I. Silverberg MD PhD MPH, Keith D. Knapp PhD, Breda Munoz PhD, Julie M. Crawford MD, Brian Calimlim DrPH, Chibuzo Obi PharmD, Ayman Grada MD, Amy S. Paller MD on behalf of the TARGET-DERM Investigators
710 Improving pediatric atopic dermatitis care: online intervention in the Deep South
Thy N. Huynh, Manoj Sharma, Summer V. Morrissette, Robert T. Brodell, Vinayak K. Nahar
711 Prolonged half-life and sustained inhibition of key inflammatory biomarkers: a phase 1 study of APG777, a high-affinity humanized IgG1 monoclonal antibody targeting IL-13
Xiu Qin Lim, Erica Winter, Kristine Nograles, Sai Thankamony, Lukas Dillinger, Carl Dambkowski
712 Positive 52-week maintenance data observed with rademikibart in patients with moderate-to-severe atopic dermatitis (SEASIDE CHINA)
Jianzhong Zhang, Jonathan I. Silverberg, Jiawang Guo, Jili Yun, Wuban Pan, Zheng Wei, Raúl Collazo
713 Real-world baseline characteristics and persistence in adult patients initiating tralokinumab in the CorEvitas atopic dermatitis registry
Eric Simpson, Sanjeev Balu, C. Jean Choi, Alvin Li, Oksana Pugach, Shannon Schneider, Jonathan Silverberg
714 Real-world effectiveness of persistent tralokinumab use on clinician and patient-reported outcomes in patients with atopic dermatitis in the CorEvitas atopic dermatitis registry
Jonathan Silverberg, Sanjeev Balu, C. Jean Choi, Alvin Li, Oksana Pugach, Shannon Schneider, Eric Simpson
715 Ruxolitinib: what’s stopping us?
Tiffany N Truong, DO; Nicole M Chase, MD
717 Clinical Efficacy, Safety, and Pharmacokinetic Profile of Bosakitug (BSI-045B), an Anti-Thymic Stromal Lymphopoietin (TSLP) mAb in a Phase 2 Study of Moderate and Severe Atopic Dermatitis Subjects
Jennifer L. Parish, James E. Appel, Jonathan I. Silverberg, Chu Zhang, Shu-Wen Teng, Jing Zhang, Qinghua Yu, Xiaodong F. Liu, Mingjiu Chen and Hugh M. Davis